AVBP vs. AVTE, CALT, YMAB, IGMS, PHAT, GHRS, STOK, PHAR, ORIC, and ATXS
Should you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include Aerovate Therapeutics (AVTE), Calliditas Therapeutics AB (publ) (CALT), Y-mAbs Therapeutics (YMAB), IGM Biosciences (IGMS), Phathom Pharmaceuticals (PHAT), GH Research (GHRS), Stoke Therapeutics (STOK), Pharming Group (PHAR), ORIC Pharmaceuticals (ORIC), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical preparations" industry.
Aerovate Therapeutics (NASDAQ:AVTE) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, community ranking, risk, profitability, valuation and earnings.
In the previous week, Aerovate Therapeutics had 21 more articles in the media than ArriVent BioPharma. MarketBeat recorded 26 mentions for Aerovate Therapeutics and 5 mentions for ArriVent BioPharma. Aerovate Therapeutics' average media sentiment score of 1.07 beat ArriVent BioPharma's score of 0.48 indicating that ArriVent BioPharma is being referred to more favorably in the news media.
Aerovate Therapeutics' return on equity of 0.00% beat ArriVent BioPharma's return on equity.
Aerovate Therapeutics received 10 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 65.38% of users gave Aerovate Therapeutics an outperform vote.
9.5% of ArriVent BioPharma shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Aerovate Therapeutics currently has a consensus price target of $47.00, suggesting a potential upside of 132.67%. ArriVent BioPharma has a consensus price target of $29.25, suggesting a potential upside of 47.06%. Given ArriVent BioPharma's higher possible upside, analysts clearly believe Aerovate Therapeutics is more favorable than ArriVent BioPharma.
Summary
ArriVent BioPharma beats Aerovate Therapeutics on 7 of the 11 factors compared between the two stocks.
Get ArriVent BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ArriVent BioPharma Competitors List
Related Companies and Tools
